Hudson Headwaters 340B is staying up to date on breaking developments with manufacturer restrictions on 340B purchasing. The latest notice from Boehringer Ingelheim Pharmaceuticals, Inc (Boehringer) has outlined the unfortunate decision to stop offering 340B pricing to covered entities that utilize contract pharmacy arrangements. It is important to note that those with grantee status are excluded from these limits.
A recent letter from Boehringer outlining the change says, “For orders placed on or after August 1, 2021, BI will ship products purchased at the 340B price exclusively to locations registered as a 340B covered entity or their child site locations and will not facilitate shipment to commercial contract pharmacies. For orders placed on or after August 1, 2021, except as provided below, BI will ship products purchased at the 340B price exclusively to locations registered as a 340B covered entity or their child site locations and will not facilitate shipment to commercial contract pharmacies.”
Boehringer is allowing one contract pharmacy arrangement per entity for those without an entity-owned pharmacy. Designations will need to be made with a registration on the Second Sight Solutions page. Clients of Hudson Headwaters 340B are encouraged to maintain close contact with their designated client services representative to provide approval letters during this process. Once the registration and letter are received, our team will remove the NDC exclusions applied and allow eligibility qualifications and purchasing to resume.
Covered entities should also review the final list of Boehringer’s contract pharmacy applicable NDC’s and make sure their TPA is able to properly apply exclusions to those drugs not listed. Several legal proceedings are taking place for the original manufacturers that began this practice. As solid or clear developments are reached, Hudson 340B will adjust exclusions as the outcomes allow, keeping our partners informed of the progress.